Evidence map›Paper›PMID 35986902›Full record

ArticleLiver international : official journal of the International Association for the Study of the Liver2022

Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma.

Mathew Vithayathil, Antonio D'Alessio, Claudia A M Fulgenzi, Naoshi Nishida, Martin Schönlein, Johann von Felden, Kornelius Schulze, Henning Wege, Anwaar Saeed, Brooke Wietharn and 25 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Liver international : official journal of the International Association for the Study of the Liver, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 4 pooled it
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 4 syntheses or guidelines pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Observational
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

35 authors at 15 institutions in 7 countries.

Mathew VithayathilDepartment of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Antonio D'AlessioDepartment of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Claudia A M FulgenziDepartment of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Naoshi NishidaDepartment of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
Martin SchönleinDepartment of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID 0000-0002-1010-0975
Johann von FeldenDepartment of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Kornelius SchulzeDepartment of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID 0000-0001-7078-9260
Henning WegeDepartment of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Anwaar SaeedDivision of Medical Oncology, Department of Medicine, Kansas University Cancer Center, Kansas City, Kansas, USA.
Brooke WietharnDivision of Medical Oncology, Department of Medicine, Kansas University Cancer Center, Kansas City, Kansas, USA.
Hannah HildebrandDivision of Medical Oncology, Department of Medicine, Kansas University Cancer Center, Kansas City, Kansas, USA.
Linda WuDivision of Hematology/Oncology, Department of Medicine, Tisch Cancer Institute, Mount Sinai Hospital, New York, New York, USA.
Celina AngDivision of Hematology/Oncology, Department of Medicine, Tisch Cancer Institute, Mount Sinai Hospital, New York, New York, USA.
Thomas U MarronDivision of Hematology/Oncology, Department of Medicine, Tisch Cancer Institute, Mount Sinai Hospital, New York, New York, USA.
Arndt WeinmannI. Medical Department, University Medical Center Mainz, Mainz, Germany.
Peter R GalleI. Medical Department, University Medical Center Mainz, Mainz, Germany.
Dominik BettingerDepartment of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Faculty of Medicine, Freiburg University Medical Center, University of Freiburg, Freiburg, Germany.ORCID 0000-0002-8782-8729
Bertram BengschDepartment of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Faculty of Medicine, Freiburg University Medical Center, University of Freiburg, Freiburg, Germany.
Arndt VogelHannover Medical School, Hannover, Germany.
Lorenz BalcarDivision of Gastroenterology & Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-6708-3061
Bernhard ScheinerDivision of Gastroenterology & Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-4904-5133
Pei-Chang LeeDivision of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Yi-Hsiang HuangDivision of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.ORCID 0000-0001-5241-5425
Suneetha AmaraDivision of Hematology/Oncology, East Carolina University, Greenville, North Carolina, USA.
Mahvish MuzaffarDivision of Hematology/Oncology, East Carolina University, Greenville, North Carolina, USA.
Abdul Rafeh NaqashDivision of Hematology/Oncology, East Carolina University, Greenville, North Carolina, USA.
Antonella CammarotaDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.
Nicola PersoneniDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.ORCID 0000-0002-7995-272X
Tiziana PressianiMedical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Italy.
Matthias PinterDivision of Gastroenterology & Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-7260-532X
Alessio CortelliniDepartment of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Masatoshi KudoDepartment of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.ORCID 0000-0002-4102-3474
Lorenza RimassaDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.ORCID 0000-0001-9957-3615
David J PinatoDepartment of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Rohini SharmaDepartment of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK.ORCID 0000-0003-2441-549X
Hammersmith Hospital · GBHumanitas University · ITUniversität Hamburg · DEEast Carolina University · USMedical University of Vienna · ATMount Sinai Hospital · USThe University of Kansas Cancer Center · USJohannes Gutenberg University Mainz · DEKindai University · JPUniversity of Freiburg · DEIRCCS Humanitas Research Hospital · ITMedizinische Hochschule Hannover · DENational Yang Ming Chiao Tung University · TWTaipei Veterans General Hospital · TWUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · IT

Funding

Cancer Research UK RCCPDB-NOV21/100008Wellcome Trust PS3416
6 · The paper itself

Abstract

BACKGROUND AND

aimsCombination atezolizumab/bevacizumab is the gold standard for first-line treatment of unresectable hepatocellular carcinoma (HCC). Our study investigated the efficacy and safety of combination therapy in older patients with HCC.

methods191 consecutive patients from eight centres receiving atezolizumab and bevacizumab were included. Overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and disease control rate (DCR) defined by RECIST v1.1 were measured in older (age ≥ 65 years) and younger (age < 65 years) age patients. Treatment-related adverse events (trAEs) were evaluated.

resultsThe elderly (n = 116) had higher rates of non-alcoholic fatty liver disease (19.8% vs. 2.7%; p < .001), presenting with smaller tumours (6.2 cm vs 7.9 cm, p = .02) with less portal vein thrombosis (31.9 vs. 54.7%, p = .002), with fewer patients presenting with BCLC-C stage disease (50.9 vs. 74.3%, p = .002). There was no significant difference in OS (median 14.9 vs. 15.1 months; HR 1.15, 95% CI 0.65-2.02 p = .63) and PFS (median 7.1 vs. 5.5 months; HR 1.11, 95% CI 0.54-1.92; p = .72) between older age and younger age. Older patients had similar ORR (27.6% vs. 20.0%; p = .27) and DCR (77.5% vs. 66.1%; p = .11) compared to younger patients. Atezolizumab-related (40.5% vs. 48.0%; p = .31) and bevacizumab-related (44.8% vs. 41.3%; p = .63) trAEs were comparable between groups. Rates of grade ≥3 trAEs and toxicity-related treatment discontinuation were similar between older and younger age patients. Patients 75 years and older had similar survival and safety outcomes compared to younger patients.

conclusionsAtezolizumab and bevacizumab therapy is associated with comparable efficacy and tolerability in older age patients with unresectable HCC.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsAgedAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabHumansAntibodies, Monoclonal, HumanizedatezolizumabBevacizumabanti-programmed death-ligandanti-vascular endothelial growth factorcheckpoint inhibitorcirrhosisimmunotherapy

Identifiers

PMID35986902
PMCPMC9825835
OpenAlexW4292444180

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.